• Dr. Davide Giuseppe Ribaldone, Head of the group
• Dr.ssa Chiara Rosso, Research Technician
• Dr. Gian Paolo Caviglia, Assistant professor
• Dr.ssa Maria Lorena Abate, Research Technician
• Dr.ssa Antonella Olivero, Research Technician
• Dr.ssa Marta Vernero, PhD candidate
• Dr.sa Nuria Perez Diaz Del Campo, Research Fellow
• Dr.sa Antonella Conte, Research Fellow

San Giovani Antica Sede, Via Cavour 31, Turin, Italy.

Mail: davidegiuseppe.ribaldone@unito.it

• Dr. Davide Giuseppe Ribaldone
• Dr. Gian Paolo Caviglia
• Dr.ssa Marta Vernero
• Dr.sa Antonella Conte

• Collection of blood, stool, urine, saliva, and histological samples of patients with IBD and their storage in the IBD biobank, in collaboration with the Karolinska University Hospital (Stockholm, Sweden) 
• Circulating cytokines, zonulin and their role in the prediction of pharmacological response in patients with IBD treated with biological drugs, in collaboration with the “Department of Translational Research and New Technologies in Medicine and Surgery”, University of Pisa
• Determination of biological drugs trough levels and their ability to predict therapy response, in collaboration with the Amedeo di Savoia Hospital, SC Clinical Biochemistry and University of Pisa
• Role of the Nicotinamide phosphoribosyltransferase as biomarker of IBD, in collaboration with the Department of Pharmaceutical Sciences, Piemonte Orientale University, Novara
• Role of volatile organic metabolites (VOMs) and microbiome in IBD, in collaboration with Department of Agricultural, Forestry and Food Sciences of University of Turin
• Studies about the link between parodontitis and IBD in collaboration with Dental School of University of Turin

• List of publications of the last 3 years

1. Caviglia GP, Tucci A, Pellicano R, Fagoonee S, Rosso C, Abate ML, Olivero A, Armandi A, Vanni E, Saracco GM, Bugianesi E, Astegiano M, Ribaldone DG. Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report. J Clin Med. 2020 Jul 23;9(8):2353. doi: 10.3390/jcm9082353. PMID: 32717980; PMCID: PMC7464152.

2. Bertani L, Caviglia GP, Antonioli L, Pellicano R, Fagoonee S, Astegiano M, Saracco GM, Bugianesi E, Blandizzi C, Costa F, Ribaldone DG. Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. J Clin Med. 2020 May 2;9(5):1323. doi: 10.3390/jcm9051323. PMID: 32370274; PMCID: PMC7290461.

3. Caviglia GP, De Blasio F, Vernero M, Armandi A, Rosso C, Saracco GM, Bugianesi E,  Astegiano M, Ribaldone DG. Efficacy of a Preparation Based on Calcium Butyrate,  Bifidobacterium bifidum, Bifidobacterium lactis, and Fructooligosaccharides in the  Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study.  J Clin Med. 2021 Oct 26;10(21):4961. doi: 10.3390/jcm10214961. PMID: 34768480;  PMCID: PMC8585056.

4. Caviglia GP, Rosso C, Stalla F, Rizzo M, Massano A, Abate ML, Olivero A, Armandi A, Vanni E, Younes R, Fagoonee S, Pellicano R, Astegiano M, Saracco GM, Bugianesi E, Ribaldone DG. On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases. J Clin Med. 2020 Mar 15;9(3):800. doi: 10.3390/jcm9030800. PMID: 32183476; PMCID: PMC7141255.

5. Ribaldone DG, Caviglia GP, Abdulle A, Pellicano R, Ditto MC, Morino M, Fusaro E, Saracco GM, Bugianesi E, Astegiano M. Adalimumab Therapy ImprovesIntestinal Dysbiosis in Crohn's Disease. J Clin Med. 2019 Oct 9;8(10):1646. doi: 10.3390/jcm8101646. PMID: 31601034; PMCID: PMC6832711.

Ricerca biomedica condotta da giovani ricercatori 2020

Grant Awarded December 2020
Total funding EUR 249,300
Funding agency Fondazione CARIPLO
Grant reference https://www.fondazionecariplo.it/it/bandi/ricerca/bando-con-scadenza-ricerca-biomedica-condotta-da-giovani-ricercatori.html
Research institution University of Padova
Principal investigators Cristina Travelli
Co-investigators Davide Giuseppe Ribaldone, Ambra Grolla, Luca Pastorelli, Gian Paolo Caviglia, Erika Del Grosso
Secondary institutions Università degli Studi di Torino

Fondi di Ricerca locale 2020

Grant Awarded October 2020
Total funding EUR 2,641
Funding agency University of Turin
Grant reference https://www.unito.it/ricerca/finanziamenti-la-ricerca/ricerca-nazionale-e-regionale/ricerca-finanziata-dalluniversita-ex
Research institution Università degli Studi di Torino
Principal investigators Davide Giuseppe Ribaldone

CALL FAST TRACK COVID19

Grant Awarded October 2020
Funding agency Area Science Park
Grant reference https://www.areasciencepark.it/piattaforme-tecnologiche/call-fast-track/
Research institution Italian National Research Council
Principal investigators Sharmila Fagoonee, Antonio D’Avolio
Co-investigators Davide Giuseppe Ribaldone
Secondary institutions Università degli Studi di Torino

1. Caviglia GP, Tucci A, Pellicano R, Fagoonee S, Rosso C, Abate ML, Olivero A, Armandi A, Vanni E, Saracco GM, Bugianesi E, Astegiano M, Ribaldone DG. Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report. J Clin Med. 2020 Jul 23;9(8):2353. doi: 10.3390/jcm9082353. PMID: 32717980; PMCID: PMC7464152.

2. Bertani L, Caviglia GP, Antonioli L, Pellicano R, Fagoonee S, Astegiano M, Saracco GM, Bugianesi E, Blandizzi C, Costa F, Ribaldone DG. Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. J Clin Med. 2020 May 2;9(5):1323. doi: 10.3390/jcm9051323. PMID: 32370274; PMCID: PMC7290461.

3. Caviglia GP, De Blasio F, Vernero M, Armandi A, Rosso C, Saracco GM, Bugianesi E,  Astegiano M, Ribaldone DG. Efficacy of a Preparation Based on Calcium Butyrate,  Bifidobacterium bifidum, Bifidobacterium lactis, and Fructooligosaccharides in the  Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study.  J Clin Med. 2021 Oct 26;10(21):4961. doi: 10.3390/jcm10214961. PMID: 34768480;  PMCID: PMC8585056.

4. Caviglia GP, Rosso C, Stalla F, Rizzo M, Massano A, Abate ML, Olivero A, Armandi A, Vanni E, Younes R, Fagoonee S, Pellicano R, Astegiano M, Saracco GM, Bugianesi E, Ribaldone DG. On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases. J Clin Med. 2020 Mar 15;9(3):800. doi: 10.3390/jcm9030800. PMID: 32183476; PMCID: PMC7141255.

5. Ribaldone DG, Caviglia GP, Abdulle A, Pellicano R, Ditto MC, Morino M, Fusaro E, Saracco GM, Bugianesi E, Astegiano M. Adalimumab Therapy ImprovesIntestinal Dysbiosis in Crohn's Disease. J Clin Med. 2019 Oct 9;8(10):1646. doi: 10.3390/jcm8101646. PMID: 31601034; PMCID: PMC6832711.

• Terzo Tempo - conference - "La cura dell'epatite C: una rivoluzione della medicina" - 31/01/23 
• Notte dei Ricercatori 2021 - A spasso con il sapere
• Notte dei Ricercatori 2021 - I retroscienza 
• I retroscienza 2020 - Incontro con le Scuole
• Notte Europea dei Ricercatori 2020
• Biennale Tecnologia – 2020